Novo Nordisk's CFO expects US growth boost this year
In spite of price pressure in the insulin business and increased US competition Novo Nordisk's CFO expects the company to grow its US business in 2021.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk expects to turn its US growth up a notch, since the company is back to growing on this market after a stagnation and price pressure-riddled 2019.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk expects 5-9 percent sales growth in 2021
For subscribers
Mads Krogsgaard Thomsen resigns from Novo Nordisk
For subscribers
